Shares of Assertio Therapeutics ASRT rose 9% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).
Revenue of $20,917,000 less by 63.89% from the same period last year, which beat the estimate of $11,300,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 11, 2020
Time: 08:01 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/vryis85c
Technicals
52-week high: $4.92
Company's 52-week low was at $0.55
Price action over last quarter: Up 10.80%
Company Description
Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
